A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria-Reference-Cited by-同舟云学术

A double-blind, randomized, placebo-controlled trial of combined calcitriol and ergocalciferol versus ergocalciferol alone in chronic kidney disease with proteinuria

Published:2017-01-14 Issue:1 Volume:18 Page:
ISSN:1471-2369
Container-title:BMC Nephrology
language:en
Short-container-title:BMC Nephrol

Author:

Susantitaphong Paweena,Nakwan Siriwan,Peerapornratana Sadudee,Tiranathanagul Khajohn,Katavetin Pisut,Srisawat Nattachai,Praditpornsilpa Kearkiat,Eiam-Ong Somchai

Funder

Ratchadapiseksompotch Research Fund

Thailand Research Fund

Publisher

Springer Science and Business Media LLC

Subject

Nephrology

Link

http://link.springer.com/content/pdf/10.1186/s12882-017-0436-6.pdf

Reference28 articles.

1. Stanifer JW, Muiru A, Jafar TH, Patel UD. Chronic kidney disease in low- and middle-income countries. Nephrol Dial Transplant. 2016;31(6):868–74. doi: 10.1093/ndt/gfv466 . Epub 2016 Feb 4.

2. Astor BC, Matsushita K, Gansevoort RT, van der Velde M, Woodward M, Levey AS, et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int. 2011;79:1331–40.